Boldt’s data were fake in 1996 paper

Ludwigshafen Hospital, via Wikimedia http://commons.wikimedia.org/wiki/File:Klinikum_Ludwigshafen_Nordseite.jpg
Ludwigshafen Hospital, via Wikimedia http://commons.wikimedia.org/wiki/File:Klinikum_Ludwigshafen_Nordseite.jpg

Update, 4 p.m. EST, 10/29/14: As a commenter points out, we didn’t quite get this one right. The Boldt paper that has been retracted was not previously retracted for lack of IRB approval. Rather, it was a heretofore unretracted article, from 1996, which German investigators have determined contained faked data. We’ve made edits below using strikethroughs, and have changed the headline to better reflect the content. We apologize for the errors.

We’ve commented before on the fact that we’ve noticed there’s often more to retractions whose stated reason is lack of institutional review board (IRB) approval. We can understand editors’ inclination to act as quickly as possible to issue a retraction, the scientific publishing equivalent of jailing Al Capone for tax evasion. But we appreciate it even more when said editors return to the scene of the crime, as it were, when new important details come out.

Case in point: Anesthesia & Analgesia has amended its retraction of a 2009 1996 study by Joachim Boldt — who with nearly 90 retractions once held the record in that department — based on findings that the data in that paper were fabricated.

The article was titled “Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy,” “The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patient.”  had previously been retracted because Boldt had failed to obtain adequate ethics approval for the research. But now comes this, According to the retraction notice from editor in chief Steven Shafer: Continue reading Boldt’s data were fake in 1996 paper

“Our real intention was to emphasize, not plagiarize”

joms.13692132This one’s not a retraction, but rather a back and forth of letters to the editor concerning accusations of plagiarism.

Dentists Bryan and Paul Jacobs, a father and son team, wrote a paper describing a novel surgical technique in March 2013. In October 2013, several Croatian dentists published their own paper using the technique.

A year later, the story has gotten a little more interesting. The November issue of the Journal of Oral and Mixillofacial Surgery, which published the second article, has two letters. One, from the Jacobses, accuses the Croatian authors of plagiarism. The second is a response from author Dragana Gabrić Pandurić, claiming “our real intention was to emphasize, not plagiarize, their work.”

Here’s the letter from Bryan and Paul Jacobs (paywalled): Continue reading “Our real intention was to emphasize, not plagiarize”

Heart paper will go on, but only in the first of two journals it was published in

Cardiovascular ResearchA cardiovascular group has retracted a conference proceeding abstract, because it too closely resembled a paper they published prior to the conference.

The last author is baffled as to why the journal couldn’t have made that call before they published the abstract.

Here’s the notice for “Increased beta-adrenergic inotropy in ventricular myocardium from Trpm4 knockout mice”: Continue reading Heart paper will go on, but only in the first of two journals it was published in

Failure to disclose drug company sponsor among litany of reasons for cancer retraction

tumor biologyThis one’s a real mess.

In June, a paper in Tumor Biology was retracted for at least four reasons, including bad data and hiding a trial sponsor (Merck). Some people who contributed work weren’t cited; at least one author had no idea his name would be on it. And that’s just what they tell us in the notice.

Here’s the notice for “Neutropenia and invasive fungal infection in patients with hematological malignancies treated with chemotherapy: a multicenter, prospective, non-interventional study in China:” Continue reading Failure to disclose drug company sponsor among litany of reasons for cancer retraction

Dr. Oz: Following green coffee bean diet retraction, site scrubbed, “further study is needed”

green coffee beanOn Monday, we were first to report that a study of green coffee bean extract for weight loss touted on the Dr. Oz Show had been retracted.

That story has been widely picked up by the media, including The Washington Post, which yesterday reported that the show had posted a statement about the development: Continue reading Dr. Oz: Following green coffee bean diet retraction, site scrubbed, “further study is needed”

Doing the right thing: Authors retract PNAS paper when new experiments show “conclusion was incorrect”

pnascoverResearchers in Sweden and Australia have retracted a paper in the Proceedings of the National Academy of Sciences (PNAS) after follow-up experiments disproved their conclusions.

Here’s the notice for “Dominant suppression of inflammation by glycan-hydrolyzed IgG,” which is signed by all nine of the paper’s authors: Continue reading Doing the right thing: Authors retract PNAS paper when new experiments show “conclusion was incorrect”

Authors retract green coffee bean diet paper touted by Dr. Oz

green coffee beanTwo authors of a 2012 paper sponsored by a company that made grand claims about green coffee bean extract’s abilities to help people lose weight have retracted it. The study was cited by The Dr. Oz Show, and last month it cost the company a $3.5 million settlement with the Feds.

Here’s the notice for “Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects,” a paper originally published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy: Continue reading Authors retract green coffee bean diet paper touted by Dr. Oz

Journal expresses concerns over “possible data irregularities” in paper from Army medical center docs

JAADThe Journal of the American Academy of Dermatology has issued an expression of concern about a 2012 article reporting the experience of military burn unit treating a rare ailment called toxic epidermal necrolysis.

According to the notice, which is behind a paywall (for shame!), the paper appears to have overstated the number of cases the hospital itself has treated of the life-threatening condition: Continue reading Journal expresses concerns over “possible data irregularities” in paper from Army medical center docs

Authors retract HER-2 endometrial cancer paper for 2x publication

OGSFile this one under strange excuses.

A cancer paper was retracted on September 17 for a double publication. According to the notice in which the authors admit to duplicating the “opening to the readers,” which we assume is the introduction, there was no need to cite the article “because it had not yet been printed at that time.”

Here’s the notice for “The effect of HER-2 polymorphism according to age on the risk and pathologic feature of endometrial cancer”: Continue reading Authors retract HER-2 endometrial cancer paper for 2x publication

Asthma study yanked for serious ethical violations

springerplusA paper in SpringerPlus on treating asthma with antioxidants was retracted on September 25 for something of a trifecta of ethical problems.

The retraction notice indicates that the patients never consented, there was no ethical review, and the university supposedly overseeing the study had no knowledge of it:

Continue reading Asthma study yanked for serious ethical violations